Hepatitis D: Symptoms, Tests, Treatment and Hepatitis B Prevention

Direct answer. Hepatitis D is a liver infection caused by HDV that requires hepatitis B virus. It can occur with a new hepatitis B infection or develop in someone who already has hepatitis B. Tests, liver assessment and specialist care matter even when symptoms are absent. In May 2026 the FDA approved the first US treatment for selected adults with chronic HDV, through accelerated approval; that status does not establish improvement in long-term clinical outcomes. NIDDK definition; actual FDA approval.

Table of contents

• Evidence summary
• What hepatitis D is: coinfection and superinfection
• How HDV depends on HBV and spreads
• Current treatment: eligibility and accelerated-approval limits
• Alcohol, nutrition and the limits of liver supplements
• Testing: virus detection and liver assessment
• Jaundice, bleeding and severe-illness warning signs
• Treatment interruption, reactions and medicine review
• Pregnancy, children and advanced liver disease
• Prevention, access and continuing follow-up
• Laboratory antiviral effects versus clinical outcomes
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

Confidence is good in the virus distinctions, testing roles and urgency of the precautions described. Treatment statements explain attributed clinical care; they are not a newly conducted systematic review or financially cleared numerical efficacy ranking. An independently verified supplement replacement was not established. Public funding does not make every underlying drug or vaccine trial independent.

What hepatitis D is: coinfection and superinfection

HDV is a distinct virus that needs HBV to infect a person. Coinfection means hepatitis B and D are acquired together. Superinfection means hepatitis D is acquired by someone already infected with hepatitis B. These terms describe the infection history; they are not interchangeable measures of current liver damage. Original patient explanation.

Hepatitis D can cause acute illness or persist as chronic infection. A person may not know about the underlying hepatitis B before HDV is investigated. Symptoms cannot establish whether both viruses are present, when infection began or whether the liver has developed scarring. Bring earlier hepatitis test results to the assessment rather than relying on a remembered diagnosis label.

The reviewed NIDDK page explains that hepatitis D can produce serious liver complications, including cirrhosis and liver failure. That possibility supports timely assessment; it does not supply an individual prognosis. The infection history, current viral findings and existing liver condition all matter. Complication context.

How HDV depends on HBV and spreads

The hepatitis B connection concerns viral biology, not merely two illnesses occurring by chance. HDV relies on HBV. Managing hepatitis B and evaluating hepatitis D therefore belong in one coordinated plan, while tests and treatment goals for the two viruses remain distinct. A reassuring hepatitis B result should not be interpreted as proof that every hepatitis D question is settled. Dependency and care context.

The NIDDK source describes spread through contact with infected blood or other body fluids, including shared injecting equipment and sexual exposure. Ordinary social contact is a different route: sharing a meal or being near someone does not have the same meaning as blood exposure. Avoid stigma while taking appropriate precautions around blood-contaminated equipment and personal items. Transmission and everyday-contact distinction.

Tell the clinician about a recent possible exposure, an earlier HBV diagnosis, injecting equipment, sexual exposure and relevant procedures. These details support testing and prevention advice; they do not prove the source of an infection. Local screening, occupational-exposure and partner-care arrangements can differ.

Current treatment: eligibility and accelerated-approval limits

Treatment requires a hepatitis specialist to establish chronic infection, current liver status and individual suitability. The FDA announcement dated May 22, 2026 records US approval of Hepcludex, bulevirtide-gmod, for adults with chronic HDV infection who have no cirrhosis or compensated cirrhosis. The current US label is specific; it does not establish eligibility for every age, liver stage or country. Actual approval announcement.

This was accelerated approval based on HDV RNA and ALT findings. The actual label states that improvement in clinical disease outcomes has not been established, and continued approval may depend on confirmatory evidence. A fall in a viral or liver-enzyme marker is a different result from demonstrating fewer liver failures, transplants or deaths. No clinical-outcome benefit percentage is supplied here. Actual indication and approval limitation.

The older December 2024 NIDDK page says that no medicine was then approved in the United States. That statement is obsolete after the 2026 approval and is excluded from this guide. The source remains useful for selected definitions and prevention roles; its old treatment menu is not treated as complete current guidance. Dated patient original.

The team should also address hepatitis B, existing scarring and any complications. A medicine prescribed for HBV does not automatically answer whether active HDV has been controlled. Treatment options, referral pathways and licensing outside the US require local review. This article explains the documented status and limits rather than selecting a drug, dose or course for a reader.

Alcohol, nutrition and the limits of liver supplements

No independently verified supplement replacement for HDV care was established in the sources reviewed. A product described as a liver cleanser, antiviral herb or immune booster has not thereby demonstrated reliable virus control or prevention of liver complications. Bring the exact ingredients and product names to the hepatitis team before adding them.

The NIDDK source recommends avoiding alcohol and discussing medicines, supplements and diet with the clinician. Adequate nutrition and practical support for eating are separate from claims that a special diet eliminates HDV. Advanced liver illness may change nutritional needs; a restrictive internet regimen should not replace clinical or dietitian advice. Selected liver-care precautions.

If nausea, fatigue or financial pressure interferes with food intake or appointments, tell the team. These are practical care problems that deserve help. Feeling better after changing a diet does not confirm viral clearance, and feeling well is not a reason to cancel planned liver checks.

Testing: virus detection and liver assessment

Assessment combines the exposure and medical history with blood tests for hepatitis B and D and evaluation of liver injury. Virus detection and liver damage are different questions. The current FDA indication concerns chronic HDV; the label uses HDV RNA in describing virological assessment. A clinician should explain which result indicates virus detection and which results describe the liver. Diagnostic and liver-assessment roles; Actual chronic-infection context.

Liver-enzyme results do not identify a hepatitis virus by themselves. Likewise, a symptom such as fatigue or abdominal discomfort can have several explanations. Depending on the findings, the team may assess scarring and other complications. This is not a home diagnosis from a single abnormal laboratory value.

Ask for the results in writing, including what each test can and cannot establish, whether further testing is needed and when the next review occurs. Earlier results help distinguish a new finding from a long-standing condition. A monitoring plan should explain what would change care rather than simply repeating a test without discussing its purpose.

Jaundice, bleeding and severe-illness warning signs

New yellow eyes or skin require urgent assessment. NHS jaundice guidance. Vomiting blood, especially with faintness, confusion, black stools or feeling seriously unwell, needs emergency care. Bleeding warning signs. A known hepatitis diagnosis does not make a new symptom safe to ignore.

Poor intake with reduced urination or persistent dizziness needs prompt help. Confusion or difficulty waking is an emergency warning sign. Dehydration and emergency guidance. Use the local emergency service outside the UK; do not wait for a routine hepatitis appointment with severe illness.

Cirrhosis can require its own complication assessment and cancer surveillance. The NIDDK source describes specialist management and possible transplant evaluation when the liver fails. These are distinct care questions, not automatic outcomes for everyone with HDV. Ask which continuing checks apply to the actual liver findings. Advanced-disease context.

Treatment interruption, reactions and medicine review

The actual US bulevirtide label has a boxed warning about severe exacerbations of hepatitis B and D after discontinuation. Treatment interruption requires a plan for clinical and laboratory follow-up. Do not interpret completion of an injection supply, an access problem or an improving test as permission to stop without contacting the prescribing team. Actual boxed withdrawal warning.

The selected label also describes serious hypersensitivity reactions, including anaphylaxis, and other adverse reactions such as injection-site reactions, itching, headache or abdominal symptoms. No event rate is adopted here. Severe allergic symptoms need emergency assessment; new symptoms during treatment should be discussed with the clinician rather than automatically attributed to the underlying infection. Selected safety sections.

Share all prescriptions, over-the-counter medicines, vitamins and herbal products with the prescriber and pharmacist. A general statement about one interaction pathway is not assurance that every combination is safe. Kidney illness, other infections and medicines from another specialist can change the review. This guide supplies no self-adjustment or restart protocol.

Pregnancy, children and advanced liver disease

The May 2026 US indication covers adults with no cirrhosis or compensated cirrhosis. The selected label does not establish paediatric use under 18 or treatment suitability for decompensated liver disease. US criteria should not be exported to other jurisdictions, where licensing and access may differ. A specialist must interpret the actual current local indication. Population and indication limits.

The label describes insufficient human pregnancy information and uncertainty about breastfeeding exposure. That is a reason for individual counselling, not a blanket declaration that treatment is safe or that every pregnant person should stop it. Explain pregnancy plans, possible pregnancy and breastfeeding before a course or interruption is decided. Selected pregnancy and lactation sections.

Advanced liver disease, substantial kidney illness and other clinical circumstances need specific review. A regulatory approval is not an automatic clearance for a reader with several conditions. Ask who coordinates decisions between hepatitis, kidney, pregnancy or transplant services when those issues overlap.

Prevention, access and continuing follow-up

Hepatitis B vaccination can prevent hepatitis D by preventing the HBV infection on which HDV depends. This prevention role concerns a person susceptible to HBV. The vaccine does not remove established hepatitis B or hepatitis D; someone already infected needs the relevant clinical care. Prevention versus established infection.

Avoid sharing injecting equipment or blood-contaminated personal items and discuss sexual-exposure precautions and partner testing with the team. A person can need both treatment and practical prevention support. Local hepatitis B vaccination, contact assessment and exposure-management schedules should come from the appropriate service.

Before treatment, request a plan covering the diagnosis, liver status, medicine checks, supply arrangements, monitoring and response to missed or interrupted treatment. Cost or access barriers should be raised before a gap occurs. Regulatory approval does not guarantee funding, availability or eligibility in every health system.

Keep test results and treatment details together and share them when another service changes a medicine. Continuing liver follow-up may remain necessary even when a viral marker improves. Ask which appointments concern HDV, which concern HBV and which monitor pre-existing liver damage. Clear ownership of the plan is more useful than assuming a single improved result ends care.

Laboratory antiviral effects versus clinical outcomes

Blocking a viral pathway or reducing HDV RNA is not the same outcome as fewer liver failures, transplants or deaths. The actual US label distinguishes its accelerated-approval markers from clinical disease outcomes. Cell and animal findings cannot settle personal treatment suitability or establish a supplement replacement. An independent efficacy assessment requires appropriate human comparisons, meaningful outcomes, safety follow-up and the original financial chain; maker-related efficacy is excluded from this guide’s independent verdict.

Funding and source roles

The illness has no corporate owner or manufacturing country. Pharmaceutical and vaccine manufacturers, diagnostic suppliers, care providers and supplement sellers can earn income around prevention, diagnosis and treatment. The source audit below separates institutional income, permitted gift routes, outside-reviewer interests and original treatment evidence. Unknown allocation remains unknown; an interest is not an allegation of improper conduct.

A funding tier measures proximity to the subject; a credibility grade reflects transparency and accuracy incentives. Tier4 producer or commercially supported efficacy is excluded from an independent benefit verdict even when a source is free. Separate 2025–2026 disclosures do not establish payments for a December 2024 NIDDK page. The infographic summarises these disclosed relationships; it does not invent proportions of a page budget.

Frequently asked questions

Can hepatitis D occur without hepatitis B?
No. HDV requires HBV infection.

What is superinfection?
It means HDV infection in someone who already has hepatitis B.

Is the old statement that no US medicine is approved still current?
No. The FDA announced a first approved treatment for a specified adult chronic-HDV population in May 2026.

Does accelerated approval establish better long-term clinical outcomes?
No. The selected actual label says improvement in clinical disease outcomes has not been established.

Can I stop treatment when tests improve?
No self-stopping rule is supplied. The bulevirtide label warns of severe hepatitis B and D flares after stopping; speak to the prescribing team.

Will hepatitis B vaccination treat established hepatitis D?
No. Its role is prevention of HBV in a susceptible person, which also prevents HDV infection.

Sources and funding notes

• NIDDK hepatitis D, December 2024 — Virus dependency, transmission, assessment and prevention; obsolete US approval statement excluded.
• NHS hepatitis overview, December 31, 2025 — Virus distinctions and general symptom/complication context.
• FDA first US chronic hepatitis D treatment approval, May 22, 2026 — Actual jurisdiction-specific approval, eligibility and accelerated-approval status.
• Actual May 2026 FDA-approved Hepcludex label,43pages; selected indication/warning sections — Selected approved indication and safety context only; maker-related efficacy excluded.
• Actual FDA orphan-product sponsor and approval record — Gilead sponsor identity, last-reported address and US approval date.
• NHS jaundice, January 22, 2024 — Urgent assessment of new yellow eyes or skin.
• NHS vomiting blood, August 18, 2025 — Emergency assessment of bleeding with illness or faintness.
• NHS dehydration, May 1, 2026 — Poor-intake and emergency warning signs.
• NIDDK actual funding, gifts and location FAQ, May 2024 — Institutional provenance, not actual donor allocation.
• NIDDK budget/legislative index, May 2024 review, newer requests listed — Proposals distinguished from actual appropriations.
• NIDDK actual FY2027 justification,21pages, containing separate FY2026 enacted table — Institutional enacted funding, not hepatitis/page allocation; FY2027 request kept separate.
• NHS national website content and funding policy, October 2022 — National website editorial/financial provenance.
• CDC actual FY2026 operating plan,4pages — Whole programme budget, not a page/trial allocation.
• CDC original gift policy, effective 2016; reviewed 2022,24pages — Direct gifts, foundation transfers and conflict-review requirements.
• CDC actual public-site contact/provenance — Atlanta institutional location.
• FDA actual FY2026 operating plan,5pages; selected first-page finance — Public budget authority and regulated-industry user fees; not application/page allocation.
• FDA actual visitor-information contact — White Oak, Silver Spring institutional location.
• Lok/Feld original 2025 guideline financial declarations, 45 pages — Separate credited-reviewer interests only; no attribution to the December 2024 patient page.

Actual December 2024 NIDDK and December 2025 NHS bodies, the May 22, 2026 FDA approval/sponsor record, selected indication and safety sections of the actual43-page May 2026 US label, and current selected NHS urgent-care bodies were read. The NIDDK obsolete no-approved-US-drug statement and incomplete old treatment menu are excluded. No dose, event rate, marker-response percentage, universal worldwide eligibility or improved long-term outcome claim is adopted. FDA actual FY2026 finance distinguishes public budget authority from industry user fees; a sponsor address is not a verified manufacturing site. Lok’s separate 2025 relationships are not assigned as payments for the December 2024 patient page. Current primary patient guidance and the selected financial originals were read. Complete original treatment trials, their suppliers, society ownership/backer chains and contemporaneous page-review compensation were not audited. No personal dose, brand hierarchy or trial benefit percentage is supplied. ClinicalTrials.gov listings, institutional names and accreditation do not themselves establish safety or independence.

Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.